Reported 2 months ago
Eli Lilly's stock surged after the company reported strong second-quarter results, prompting analysts to raise their targets significantly. The pharmaceutical giant's share price jumped nearly 10% shortly after the earnings announcement, with many analysts setting price targets above $1,000, citing potential continued revenue growth from successful drugs like Mounjaro and Zepbound. Despite some recent declines, the company's strong market position and revenue forecasts for 2024 suggest a bullish outlook moving forward.
Source: YAHOO